DDrare: Database of Drug Development for Rare Diseases

107. 若年性特発性関節炎［全身型若年性特発性関節炎（~2018.3）］
［臨床試験数：151，薬物数：75（DrugBank：13），標的遺伝子数：16，標的パスウェイ数：90］

Searched query = "Juvenile idiopathic arthritis", "Systemic juvenile idiopathic arthritis", "Systemic-onset juvenile idiopathic arthritis", "JIA", "SJIA"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = ACTEMRA; ACZ885; ACZ885 150 mg (Canakinumab); ACZ885 Drug Substance; ACZ885G; ANAKINRA; APD421; Abatacept; Actemra; Actemra, MRA; Anakinra; Anakinra / kineret; BARICITINIB; Baricitinib; CANAKINUMAB; CCP-690-550-10; CP; CP-690,550-10; CSs; Canakinumab; Corticosteroids; EMAPALUMAB; Emapalumab; Fully human anti-interferon gamma monoclonal antibody; Heparin; IL-6 receptor inhibitor, recombinant humanized monoclonal antibody; ILARIS; ITF2357; Ilaris; In double-blind phase: treatment with tofacitinib; In open-label phase: treatment with tofacitinib; Interferon Gamma; KINERET*SC 7SIR 100MG 0,67ML; Kineret; Kineret® or anakinra; LY3009104; Ly3009104; MRA; MRA (Actemra); MRA (tocilizumab); MRA(Tocilizumab); MRA, Actemra; MTX; Methotrexate; NI-0501; NSAIDs; Non-steroidal anti-inflammatory drugs (NSAIDs); Null; Olumiant; Pneumo23; REGN88; RIL-1RA; RO4877533 (TCZ); Recombinant antihumanized anti-human monoclonal antibody directed against the IL-6R; Recombinant human monoclonal antibody to human IL-1Beta of the IgG1/K class; Rilonacept; Rilonacept (IL-1 Trap); Ro 487-7533/F10-04; RoActemra; Roactemra; SAR153191; SAR153191 (REGN88); SARILUMAB; Sarilumab; Sarilumab SAR153191 (REGN88); TOCILIZUMAB; TOCILIZUMAB SC; TOFACITINIB CITRATE; Tocilizumab; Tocilizumab Roche; Tocilizumab SC; Tocilizumab [RoActemra/Actemra]; Tofacitinib; Tofacitinib citrate; Tofacitinibe citrate

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03932344 (ClinicalTrials.gov)	April 10, 2019	16/4/2019	Long-term Safety Study of Kineret® in Patients With Systemic Juvenile Idiopathic Arthritis (SJIA)	A Non-interventional, Post-authorization Safety Study (PASS) to Evaluate Long-term Safety of Anakinra (Kineret®) in Patients With Systemic Juvenile Idiopathic Arthritis	Still Disease, Juvenile Onset	Drug: Anakinra	Swedish Orphan Biovitrum	NULL	Completed	N/A	N/A	All	306		Italy
2	EUCTR2015-004393-16-NL (EUCTR)	04/10/2016	08/07/2016	Biomarker-guided treatment-and-stop-strategy for short acting IL-1 blockade in patients with systemic Juvenile Idiopathic Arthritis.	Biomarker-guided treatment-and-stop-strategy for recombinant IL-1receptor antagonist (anakinra) in patients with systemic Juvenile Idiopathic Arthritis. - ESTIS trial: Early Stop of targeted Treatment in children with Systemic JIA	systemic Juvenile Idiopathic Arthritis;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Trade Name: kineret® or anakinra Product Name: anakinra / kineret Product Code: not applicable INN or Proposed INN: ANAKINRA Other descriptive name: rIL-1RA	University Medical Center Utrecht	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes		Phase 4	Netherlands
3	NCT00339157 (ClinicalTrials.gov)	June 2006	16/6/2006	Interleukin-1 Receptor Antagonist (IL-1RA) (ANAKINRA) IN SEVERE SYSTEMIC-ONSET JUVENILE IDIOPATHIC ARTHRITIS	ANAkinra in Severe Juvenile Idiopathic Arthritis of Systemic Onset (ANAJIS)	Systemic-Onset Juvenile Idiopathic Arthritis	Drug: Anakinra;Biological: Pneumo23	Institut National de la Santé Et de la Recherche Médicale, France	NULL	Completed	2 Years	20 Years	Both	24	Phase 2;Phase 3	France
4	EUCTR2005-004008-36-IT (EUCTR)	27/10/2005	30/01/2012	Efficacy and safety of treatment with Anakinra in patients with CINCA/MUCKLE-WELLS syndrome and systemic juvenile idiopathic arthritis	Efficacy and safety of treatment with Anakinra in patients with CINCA/MUCKLE-WELLS syndrome and systemic juvenile idiopathic arthritis	CINCA/MUCKLE-WELLS syndrome and systemic juvenile idiopathic arthritis MedDRA version: 14.1;Level: SOC;Classification code 10010331;Term: Congenital, familial and genetic disorders;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Trade Name: KINERET *SC 7SIR 100MG 0,67ML INN or Proposed INN: Anakinra	ISTITUTO GIANNINA GASLINI	NULL	Not Recruiting			Female: yes Male: yes			Italy

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT03932344
(ClinicalTrials.gov)

April 10, 2019

16/4/2019

Long-term Safety Study of Kineret® in Patients With Systemic Juvenile Idiopathic Arthritis (SJIA)

A Non-interventional, Post-authorization Safety Study (PASS) to Evaluate Long-term Safety of Anakinra (Kineret®) in Patients With Systemic Juvenile Idiopathic Arthritis

Still Disease, Juvenile Onset

Drug: Anakinra

Swedish Orphan Biovitrum

NULL

Completed

N/A

All

306

Italy

EUCTR2015-004393-16-NL
(EUCTR)

04/10/2016

08/07/2016

Biomarker-guided treatment-and-stop-strategy for short acting IL-1 blockade in patients with systemic Juvenile Idiopathic Arthritis.

Biomarker-guided treatment-and-stop-strategy for recombinant IL-1receptor antagonist (anakinra) in patients with systemic Juvenile Idiopathic Arthritis. - ESTIS trial: Early Stop of targeted Treatment in children with Systemic JIA

systemic Juvenile Idiopathic Arthritis;Therapeutic area: Diseases [C] - Immune System Diseases [C20]

Trade Name: kineret® or anakinra
Product Name: anakinra / kineret
Product Code: not applicable
INN or Proposed INN: ANAKINRA
Other descriptive name: rIL-1RA

University Medical Center Utrecht

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

Phase 4

Netherlands

NCT00339157
(ClinicalTrials.gov)

June 2006

16/6/2006

Interleukin-1 Receptor Antagonist (IL-1RA) (ANAKINRA) IN SEVERE SYSTEMIC-ONSET JUVENILE IDIOPATHIC ARTHRITIS

ANAkinra in Severe Juvenile Idiopathic Arthritis of Systemic Onset (ANAJIS)

Systemic-Onset Juvenile Idiopathic Arthritis

Drug: Anakinra;Biological: Pneumo23

Institut National de la Santé Et de la Recherche Médicale, France

NULL

Completed

2 Years

20 Years

Both

Phase 2;Phase 3

France

EUCTR2005-004008-36-IT
(EUCTR)

27/10/2005

30/01/2012

Efficacy and safety of treatment with Anakinra in patients with CINCA/MUCKLE-WELLS syndrome and systemic juvenile idiopathic arthritis

CINCA/MUCKLE-WELLS syndrome and systemic juvenile idiopathic arthritis
MedDRA version: 14.1;Level: SOC;Classification code 10010331;Term: Congenital, familial and genetic disorders;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20]

Trade Name: KINERET *SC 7SIR 100MG 0,67ML
INN or Proposed INN: Anakinra

ISTITUTO GIANNINA GASLINI

NULL

Not Recruiting

Female: yes
Male: yes

Italy